Items where authors include "Emmerson, J"

Article

Munir, T, Emmerson, J orcid.org/0000-0002-8198-8043, Hockaday, A et al. (9 more authors) (2022) Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. British Journal of Haematology, 199 (5). pp. 707-719. ISSN 0007-1048

Emmerson, J orcid.org/0000-0002-8198-8043, Todd, S and Brown, JM orcid.org/0000-0002-2719-7064 (2021) Recommendations for designing and analysing multi-arm non-inferiority trials: a review of methodology and current practice. Trials, 22 (1). 417. ISSN 1745-6215

Allsup, D, Howard, D, Emmerson, J orcid.org/0000-0002-8198-8043 et al. (10 more authors) (2021) COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. British Journal of Haematology. ISSN 0007-1048

Emmerson, J orcid.org/0000-0002-8198-8043 and Brown, JM orcid.org/0000-0002-2719-7064 (2021) Understanding Survival Analysis in Clinical Trials. Clinical Oncology, 33 (1). pp. 12-14. ISSN 0936-6555

Proceedings Paper

Williams, C, Emmerson, J, Beggs, AD et al. (12 more authors) (2022) A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442). In: Journal of Clinical Oncology. 2022 ASCO Annual Meeting, 03-07 Jun 2022, Online & Chicago, IL, USA. American Society of Clinical Oncology .